Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 3
2014 1
2016 1
2017 1
2019 1
2020 3
2021 7
2022 5
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.
Eissing T, Goulooze SC, van den Berg P, van Noort M, Ruppert M, Snelder N, Garmann D, Lippert J, Heinig R, Brinker M, Heerspink HJL. Eissing T, et al. Among authors: snelder n. Diabetes Obes Metab. 2024 Mar;26(3):924-936. doi: 10.1111/dom.15387. Epub 2023 Nov 30. Diabetes Obes Metab. 2024. PMID: 38037539 Clinical Trial.
A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variables.
Fu Y, Taghvafard H, Said MM, Rossman EI, Collins TA, Billiald-Desquand S, Leishman D, van der Graaf PH, van Hasselt JGC, Snelder N. Fu Y, et al. Among authors: snelder n. CPT Pharmacometrics Syst Pharmacol. 2022 May;11(5):640-652. doi: 10.1002/psp4.12774. Epub 2022 Mar 18. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35213797 Free PMC article.
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.
van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, Joseph A, Garmann D, Lippert J, Eissing T. van den Berg P, et al. Among authors: snelder n. Clin Pharmacokinet. 2022 Mar;61(3):439-450. doi: 10.1007/s40262-021-01082-2. Epub 2021 Nov 13. Clin Pharmacokinet. 2022. PMID: 34773606 Free PMC article. Clinical Trial.
Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.
Goulooze SC, Snelder N, Seelmann A, Horvat-Broecker A, Brinker M, Joseph A, Garmann D, Lippert J, Eissing T. Goulooze SC, et al. Among authors: snelder n. Clin Pharmacokinet. 2022 Mar;61(3):451-462. doi: 10.1007/s40262-021-01083-1. Epub 2021 Nov 17. Clin Pharmacokinet. 2022. PMID: 34786651 Free PMC article. Clinical Trial.
Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease.
Hoefman S, Snelder N, van Noort M, Garcia-Hernandez A, Onkels H, Larsson TE, Bergmann KR. Hoefman S, et al. Among authors: snelder n. J Pharmacokinet Pharmacodyn. 2021 Feb;48(1):21-38. doi: 10.1007/s10928-020-09716-x. Epub 2020 Sep 14. J Pharmacokinet Pharmacodyn. 2021. PMID: 32929612 Free PMC article.
21 results